Trial Profile

Phase 1b/2 Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 04 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Pepinemab (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms CLASSICAL-Lung
Sponsors Vaccinex

Most Recent Events

21 Apr 2021 Results published in the Vaccinex Media Release.
05 Apr 2021 Results published in the Clinical Cancer Research
16 Oct 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com